THERAPY DOSSIER · th-359a3cb48c45

KB-R7785 in a sustained-release polymer hydrogel

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28031154 ↗2016Reported harm

Single Administration of a Sustained-Release Formulation of KB-R7785 Inhibits Tympanic Membrane Regeneration in an Animal Model.

MouseOtherCBAMalen = 20 mice, 40 perforationsLocal application to the tympanic membrane perforation within a polymer hydrogelSingle administration at the time of perforation

Model: Bilateral acute tympanic membrane perforation

A single sustained-release administration kept perforations open in 90% (36/40) at 3 months and 75% (30/40) at 6 months, falling to 22.5% (6/40) at 9 months. Inhibition of healing was the intended therapeutic aim, as an alternative to pressure equalisation tubes, so the direction of effect is coded…

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…